These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 15032571)

  • 21. Imatinib: a targeted clinical drug development.
    Capdeville R; Silberman S
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):15-20. PubMed ID: 12783370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The biology of signal transduction inhibition: basic science to novel therapies.
    Griffin J
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):3-8. PubMed ID: 11740801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current and emerging treatment options in chronic myeloid leukemia.
    Jabbour E; Cortes JE; Giles FJ; O'Brien S; Kantarjian HM
    Cancer; 2007 Jun; 109(11):2171-81. PubMed ID: 17431887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current treatment approaches for chronic myelogenous leukemia.
    Druker BJ
    Cancer J; 2001; 7 Suppl 1():S14-8. PubMed ID: 11504279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Origin of resistance to Imatinib mesylate: lessons learned from this experience].
    Roche-Lestienne C; Mahon FX; Preudhomme C
    Med Sci (Paris); 2004 Dec; 20(12):1125-30. PubMed ID: 15581468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overriding imatinib resistance with a novel ABL kinase inhibitor.
    Shah NP; Tran C; Lee FY; Chen P; Norris D; Sawyers CL
    Science; 2004 Jul; 305(5682):399-401. PubMed ID: 15256671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib.
    Mancini M; Corradi V; Petta S; Barbieri E; Manetti F; Botta M; Santucci MA
    J Pharmacol Exp Ther; 2011 Mar; 336(3):596-604. PubMed ID: 21041536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
    Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
    Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
    Xu F; Shi X; Li S; Cui J; Lu Z; Jin Y; Lin Y; Pang J; Pan J
    Bioorg Med Chem; 2010 Mar; 18(5):1806-15. PubMed ID: 20149665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
    Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
    Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic myelocytic leukemia--Part II: Approaches to and molecular monitoring of therapy.
    Randolph TR
    Clin Lab Sci; 2005; 18(1):49-56. PubMed ID: 15747786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; Cortes J; O'Brien S; Faderl S; Thomas D; Giles F; Rios MB; Shan J; Arlinghaus R
    Clin Cancer Res; 2003 Jan; 9(1):160-6. PubMed ID: 12538464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
    Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of chronic myeloid leukemia following imatinib resistance: a nursing guide to second-line treatment options.
    Bauer S; Romvari E
    Clin J Oncol Nurs; 2009 Oct; 13(5):523-34. PubMed ID: 19793709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
    Chien JH; Tang JL; Chen RL; Li CC; Lee CP
    Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. STI571: a paradigm of new agents for cancer therapeutics.
    Mauro MJ; O'Dwyer M; Heinrich MC; Druker BJ
    J Clin Oncol; 2002 Jan; 20(1):325-34. PubMed ID: 11773186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Applying the discovery of the Philadelphia chromosome.
    Sherbenou DW; Druker BJ
    J Clin Invest; 2007 Aug; 117(8):2067-74. PubMed ID: 17671641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imatinib (Gleevec) as a paradigm of targeted cancer therapies.
    Druker B
    Keio J Med; 2010; 59(1):1-3. PubMed ID: 20375651
    [No Abstract]   [Full Text] [Related]  

  • 40. Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia.
    Zeng Y; Graner MW; Feng H; Li G; Katsanis E
    Int J Cancer; 2004 Jun; 110(2):251-9. PubMed ID: 15069690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.